LSE:AZNPharmaceuticals
Is AstraZeneca Still Attractive After Its Strong 2025 Run and Pipeline Expansion?
If you are wondering whether AstraZeneca is still worth buying after its big pharma run up, or if the real upside is already priced in, you are not alone. This breakdown is designed to help you cut through the noise.
The stock has eased slightly in the last week, down around 0.4%, and is roughly flat over the last month. It is still up about 27.5% year to date and roughly 110.3% over 5 years, which provides a strong backdrop for a valuation check.
Recent headlines have focused on AstraZeneca...